Drug-related problems (DRPs) are prevalent and avoidable disease that patients experience due to drug use or nonuse. However, secondary prevention policies have not yet been systematized.
Objective:
To assess the clinical impact of a secondary prevention bundle for DRPs in patients who visited the emergency department (ED) for medicine-related problems.
Methods:
A single-center randomized clinical trial was conducted from August 28, 2019, to January 28, 2021, with 1-month follow-up. We included 769 adult patients who visited ED with a DRP associated with cardiovascular, alimentary tract, and metabolic system medications. For the intervention group, a DRP prevention bundle, consisting of a combined strategy initiated in the ED was applied. Patients in the control group received standard pharmaceutical care. Intervention was evaluated in terms of 30-day hospital readmission due to any cause.
Results:
Final analysis included 769 patients, of which 68 (8.8%) were readmitted within 30 days (control group, 40 of 386 [cumulative incidence: 10.4%]; intervention group, 28 of 383 [cumulative incidence, 7.3%]). After adjustment of the model for chronic heart failure, there was a lower incidence of hospital readmission among patients in the intervention group compared with those in the control group, odds ratio: 0.59 [95% confidence interval: 0.37-0.97]; number needed to treat (NNT) = 32. No significant differences in other outcomes were observed.
Conclusion and Relevance:
In this clinical trial, DRP prevention bundle in adjusted analysis decreased the rate of 30-day hospital readmission for any cause in patients who visited ED for a DRP.
Puig CampmanyMRis RomeuJBlázquez AndiónMBenito ValesS. Development of a comprehensive, multidisciplinary program of care for frailty in an emergency department. Eur Geriatr Med. 2019;10(1):37-46. doi:10.1007/s41999-018-0151-2
2.
ColcheroFRauRJonesOR, et al. The emergence of longevous populations. Proc Natl Acad Sci USA. 2016;113(48):E7681-E7690. doi:10.1073/pnas.1612191113
3.
NymoenLDBjörkMFlatebøTE, et al. Drug-related emergency department visits: prevalence and risk factors. Intern Emerg Med. 2022;17(5):1453-1462. doi:10.1007/s11739-022-02935-9
4.
Pharmaceutical Care Research Group, University of Granada. Third consensus of granada on drug related problems (DRP) and negative outcomes associated with medication (NOM). Ars Pharm. 2007;48(1):5-17.
5.
LazarouJPomeranzBHCoreyPN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-1205. doi:10.1001/jama.279.15.1200
6.
QueneauPBannwarthBCarpentierF, et al. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007;30(1):81-88. doi:10.2165/00002018-200730010-00008
7.
CastroIGuardiolaJMTuneuLSalaMLFausMJManguesMA. Drug-related visits to the emergency department in a Spanish University Hospital. Int J Clin Pharm. 2013;35(5):727-735. doi:10.1007/s11096-013-9795-7
8.
PatelPZedPJ. Drug-related visits to the emergency department: how big is the problem?Pharmacotherapy. 2002;22(7):915-923. doi:10.1592/phco.22.11.915.33630
9.
BaenaMIFajardoPCPintor-MármolA, et al. Negative clinical outcomes of medication resulting in emergency department visits. Eur J Clin Pharmacol. 2014;70(1):79-87. doi:10.1007/s00228-013-1562-0
10.
NivyaKSri Sai KiranVRagooNJayaprakashBSonal SekharM. Systemic review on drug related hospital admissions—a PubMed based search. Saudi Pharm J. 2015;23(1):1-8. doi:10.1016/j.jsps.2013.05.006
11.
El MorabetNUitvlugtEBvan den BemtBJFvan den BemtPMLAJanssenMJAKarapinar-ÇarkitF. Prevalence and preventability of drug-related hospital readmissions: a systematic review. J Am Geriatr Soc. 2018;66(3):602-608. doi:10.1111/jgs.15244
12.
DalleurOBeelerPESchnipperJLDonzéJ. 30-day potentially avoidable readmissions due to adverse drug events. J Patient Saf. 2021;17(5):e379-e386. doi:10.1097/PTS.0000000000000346
13.
ShehabNLovegroveMCGellerAIRoseKOWeidleNJBudnitzDS. US emergency department visits for outpatient adverse drug events, 2013-2014. JAMA. 2016;316(20):2115-2125. doi:10.1001/jama.2016.16201
14.
BainesRJLangelaanMde BruijneMC, et al. Changes in adverse event rates in hospitals over time: a longitudinal retrospective patient record review study. BMJ Qual Saf. 2013;22(4):290-298. doi:10.1136/bmjqs-2012-001126
15.
ParekhNAliKStevensonJM, et al. Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK. Br J Clin Pharmacol. 2018;84(8):1789-1797. doi:10.1111/bcp.13613
16.
SjölanderMLindholmLPfisterB, et al. Impact of clinical pharmacist engagement in ward teams on the number of drug-related readmissions among older patients with dementia or cognitive impairment: an economic evaluation. Res Social Adm Pharm. 2019;15(3):287-291. doi:10.1016/j.sapharm.2018.05.006
17.
FreitasGRMTramontinaMYBalbinottoGHughesDAHeineckI. Economic impact of emergency visits due to drug-related morbidity on a Brazilian hospital. Value Health Reg Issues. 2017;14:1-8. doi:10.1016/j.vhri.2017.03.003
18.
Plaza DíazARuiz RamosJJuanes BorregoAMBlázquez AndiónMPuig CampmanyMMangues BafalluyMA. Anticholinergic burden in patients treated for constipation in an emergency department. Emergencias. 2020;32(5):349-352.
19.
KoehlerBERichterKMYoungbloodL, et al. Reduction of 30-day postdischarge hospital readmission or emergency department (ED) visit rates in high-risk elderly medical patients through delivery of a targeted care bundle. J Hosp Med. 2009;4(4):211-218. doi:10.1002/jhm.427
20.
KjeldsenLJBirkholmTFischerH, et al. A national drug related problems database: evaluation of use in practice, reliability and reproducibility. Int J Clin Pharm. 2014;36(4):742-749. doi:10.1007/s11096-014-9957-2
21.
BachQNPeasahSKBarberE. Review of the role of the pharmacist in reducing hospital readmissions. J Pharm Pract. 2019;32(6):617-624. doi:10.1177/0897190018765500
World Health Organization Collaborating Center for Drugs Statistics Methodology. ATC/DDD index 2022. Date unknown. Accessed March 12, 2021. https://www.whocc.no/atc_ddd_index/.
Roure NuezCGorgas TornerMQDelgado SánchezOAyestaran AltunaA. Guia per a la Implantació de Programes de Conciliació de la Medicació als Centres Sanitaris. Sociedad Catalana de Farmacia Clínica. Barcelona, 2010.
27.
Espaulella-PanicotJMolist-BrunetNSevilla-SánchezD, et al. [Patient-centred prescription model to improve adequate prescription and therapeutic adherence in patients with multiple disorders]. Rev Esp Geriatr Gerontol. 2017;52(5):278-281. doi:10.1016/j.regg.2017.03.002
28.
González-BuenoJCalvo-CidonchaESevilla-SánchezDMolist-BrunetNEspaulella-PanicotJCodina-JanéC. Patient-centered prescription model to improve therapeutic adherence in patients with multimorbidity. Farm Hosp. 2018;42(3):128-134. doi:10.7399/fh.10961
29.
JuanesAGarinNManguesMA, et al. Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial. Eur J Hosp Pharm. 2018;25(5):274-280. doi:10.1136/ejhpharm-2016-001055
30.
ReisbergBFerrisSHde LeonMJCrookT. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136-1139. doi:10.1176/ajp.139.9.1136
31.
MahoneyFIBarthelDW. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61-65.
32.
SilversteinMDQinHMercerSQFongJHaydarZ. Risk factors for 30-day hospital readmission in patients ≥65 years of age. Proc (Bayl Univ Med Cent). 2008;21(4):363-372. doi:10.1080/08998280.2008.11928429
33.
SalviFRossiLLattanzioFCherubiniA. Is polypharmacy an independent risk factor for adverse outcomes after an emergency department visit?Intern Emerg Med. 2017;12(2):213-220. doi:10.1007/s11739-016-1451-5
34.
MasnoonNShakibSKalisch-EllettLCaugheyGE. What is polypharmacy? a systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-2
35.
JuanesAGarinNManguesMA, et al. Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial. Eur J Hosp Pharm. 2018;25(5):274-280. doi:10.1136/ejhpharm-2016-001055
36.
Delgado SilveiraEFernandez-VillalbaEMGarcía-Mina FreireMAlbiñana PérezMSCasajús LagranjaMPPeris MartíJF. The impact of Pharmacy Intervention on the treatment of elderly multi-pathological patients. Farm Hosp. 2015;39(4):192-202. doi:10.7399/fh.2015.39.4.8329
37.
GarinNSoleNLucasB, et al. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11(1):883. doi:10.1038/s41598-020-80560-2
38.
MartinPTamblynRBenedettiAAhmedSTannenbaumC. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA. 2018;320(18):1889-1898. doi:10.1001/jama.2018.16131
39.
DaliriSHugtenburgJGter RietG, et al. The effect of a pharmacy-led transitional care program on medication-related problems post-discharge: a before-after prospective study. PLoS ONE. 2019;14(3):e0213593. doi:10.1371/journal.pone.0213593
40.
GurwitzJHKapoorAGarberL, et al. Effect of a multifaceted clinical pharmacist intervention on medication safety after hospitalization in persons prescribed high-risk medications: a Randomized Clinical Trial. JAMA Intern Med. 2021;181(5):610-618. doi:10.1001/jamainternmed.2020.9285
41.
Karapinar-ÇarkıtFBorgsteedeSDJanssenMJA, et al. The effect of a pharmaceutical transitional care program on rehospitalisations in internal medicine patients: an interrupted-time-series study. BMC Health Serv Res. 2019;19(1):717. doi:10.1186/s12913-019-4617-9
42.
Gorgas TornerMQPàez VivesFCamós RamióJ, et al. Integrated pharmaceutical care programme in patients with chronic diseases. Farm Hosp. 2012;36(4):229-239. doi:10.1016/j.farma.2011.06.015
43.
OlesenCHarbigPBuusKMBaratIDamsgaardEM. Impact of pharmaceutical care on adherence, hospitalisations and mortality in elderly patients. Int J Clin Pharm. 2014;36(1):163-171. doi:10.1007/s11096-013-9898-1
44.
LeendertseAJde KoningGHGoudswaardAN, et al. Preventing hospital admissions by reviewing medication (PHARM) in primary care: an open controlled study in an elderly population. J Clin Pharm Ther. 2013;38(5):379-387. doi:10.1111/jcpt.12069
45.
Institute of Medicine (U. S.)Committee on Quality of Health Care in America; Kohn LT, Corrigan JM, Donaldson MS. To Err Is Human: Building a Safer Health System. Washington, DC: National Academies Press; 2000. doi:10.17226/9728
46.
de VriesSTDenigPEkhartC, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study. Br J Clin Pharmacol. 2019;85(7):1507-1515. doi:10.1111/bcp.13923
47.
BlumenthalDChernofBFulmerTLumpkinJSJ. Caring for high—need, high—cost patients—an urgent priority. N Engl J Med. 2016;375(10):909-911. doi:10.1056/NEJMp1608511
48.
McWilliamsJMSchwartzAL. Focusing on high—cost patients—the key to addressing high costs?N Engl J Med. 2017;376(9):807-809. doi:10.1056/NEJMp1612779
49.
Ravn-NielsenLVDuckertMLLundML, et al. Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission a randomized clinical trial. JAMA Intern Med. 2018;178(3):375-382. doi:10.1001/jamainternmed.2017.8274
50.
WeiLYangXLiJ, et al. Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study. J Thorac Dis. 2014;6(6):656-662. doi:10.3978/j.issn.2072-1439.2014.06.20
51.
YangXLupónJVidánMT, et al. Impact of frailty on mortality and hospitalization in chronic heart failure: a systematic review and meta-analysis. J Am Heart Assoc. 2018;7(23):e008251. doi:10.1161/JAHA.117.008251
52.
Ruiz-RamosJJuanes-BorregoAPuig-CampanyM, et al. Cost-effectiveness analysis of implementing a secondary prevention programme in those patients who visited an emergency department for drug-related problems. Int J Pharm Pract. 2022;30(5):434-440. doi:10.1093/ijpp/riac061
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
